Your browser doesn't support javascript.
loading
Immune Status and SARS-CoV-2 Viral Dynamics.
Li, Yijia; Moser, Carlee; Aga, Evgenia; Currier, Judith S; Wohl, David A; Daar, Eric S; Ritz, Justin; Greninger, Alexander L; Sieg, Scott; Parikh, Urvi M; Coombs, Robert W; Hughes, Michael D; Eron, Joseph J; Smith, Davey M; Chew, Kara W; Li, Jonathan Z.
  • Li Y; Department of Medicine, University of Pittsburgh, Pennsylvania.
  • Moser C; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
  • Aga E; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
  • Currier JS; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.
  • Wohl DA; Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill.
  • Daar ES; Lundquist Institute, Harbor-UCLA Medical Center, Torrance, California.
  • Ritz J; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
  • Greninger AL; Department of Laboratory Medicine and Pathology, University of Washington, Seattle.
  • Sieg S; Department of Medicine, Case Western Reserve University, Cleveland, Ohio.
  • Parikh UM; Department of Medicine, University of Pittsburgh, Pennsylvania.
  • Coombs RW; Department of Laboratory Medicine and Pathology, University of Washington, Seattle.
  • Hughes MD; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
  • Eron JJ; Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill.
  • Smith DM; Department of Medicine, University of California, San Diego, La Jolla.
  • Chew KW; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.
  • Li JZ; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts.
J Infect Dis ; 228(Suppl 2): S111-S116, 2023 08 31.
Article en En | MEDLINE | ID: mdl-37650232
Immunocompromised individuals are disproportionately affected by severe coronavirus disease 2019, but immune compromise is heterogenous, and viral dynamics may vary by the degree of immunosuppression. In this study, we categorized ACTIV-2/A5401 participants based on the extent of immunocompromise into none, mild, moderate, and severe immunocompromise. Moderate/severe immunocompromise was associated with higher nasal viral load at enrollment (adjusted difference in means: 0.47 95% confidence interval, .12-.83 log10 copies/mL) and showed a trend toward higher cumulative nasal RNA levels and plasma viremia compared to nonimmunocompromised individuals. Immunosuppression leads to greater viral shedding and altered severe acute respiratory syndrome coronavirus 2 viral decay kinetics. Clinical Trials Registration. NCT04518410.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article